Predicting the activity of hydroxamic acid analogues

References

• Rodrigues DA, Ferreira-Silva GÀ, Ferreira ACS, et al. Design, synthesis, and pharmacological evaluation of novel N-acylhydrazone derivatives as potent histone deacetylase 6/8 dual inhibitors. J Med Chem. 2016;59:655–670.10.1021/acs.jmedchem.5b01525
   PubMed Web of Science ®Google Scholar
• Mithraprabhu S, Kalff A, Chow A, et al. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics. 2014;9:1511–20.10.4161/15592294.2014.983367
   PubMed Web of Science ®Google Scholar
• Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res. 2007;5:981–989.10.1158/1541-7786.MCR-07-0324
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discovery. 2006;5:769–784.10.1038/nrd2133
   PubMed Web of Science ®Google Scholar
• Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discovery. 2014;13:673–691.10.1038/nrd4360
   PubMed Web of Science ®Google Scholar
• Liu T, Kuljaca S, Tee A, et al. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev. 2006;32:157–165.10.1016/j.ctrv.2005.12.006
   PubMed Web of Science ®Google Scholar
• Kozikowski AP, Chen Y, Gaysin AM, et al. Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitors – nanomolar-potency inhibitors of pancreatic cancer cell growth. ChemMedChem. 2008;3:487–501.10.1002/(ISSN)1860-7187
   PubMed Web of Science ®Google Scholar
• Bajpai A, Agarwal N, Gupta SP. A comparative 2D QSAR study on a series of hydroxamic acid-based histone deacetylase inhibitors vis-a-vis comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). Indian J Biochem Biophys. 2014;51:244–252.
   PubMed Web of Science ®Google Scholar
• Kmetzsch L. Histone deacetylases: targets for antifungal drug development. Virulence. 2015;6:535–536.10.1080/21505594.2015.1049807
   PubMed Web of Science ®Google Scholar
• Kijima M, Yoshida M, Sugita K, et al. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem. 1993;268:22429–22435.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Panobinostat: first global approval. Drugs. 2015;75:695–704.10.1007/s40265-015-0388-8
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Horwitz SM. Targeting histone deacetylases in T-cell lymphoma. Leukemia & Lymphoma. 2016:1–14.
   Web of Science ®Google Scholar
• Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92:1210–1216.10.1093/jnci/92.15.1210
   PubMed Web of Science ®Google Scholar
• Vigushin DM, Coombes RC. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2002;13:1–13.10.1097/00001813-200201000-00001
   PubMed Web of Science ®Google Scholar
• Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194–202.10.1038/35106079
   PubMed Web of Science ®Google Scholar
• Wang CG, Fu MF, Mani S, et al. Histone acetylation and the cell-cycle in cancer. Front Bioscience. 2001;6:D610–D29.10.2741/1wang1
   PubMed Web of Science ®Google Scholar
• Curtin M, Glaser K. Histone deacetylase inhibitors: the abbott experience. Curr Med Chem. 2003;10:2373–2392.10.2174/0929867033456576
   PubMed Web of Science ®Google Scholar
• Singh U, Gangwal RP, Prajapati R, et al. 3D QSAR pharmacophore-based virtual screening and molecular docking studies to identify novel matrix metalloproteinase 12 inhibitors. Mol Simul. 2013;39:385–396.10.1080/08927022.2012.731506
   Web of Science ®Google Scholar
• Roy PP, Roy K. Classical and 3D-QSAR studies of cytochrome 17 inhibitor imidazole-substituted biphenyls. Mol Simul. 2010;36:311–325.10.1080/08927020903426493
   Web of Science ®Google Scholar
• Roy PP, Roy K. Pharmacophore mapping, molecular docking and QSAR studies of structurally diverse compounds as CYP2B6 inhibitors. Mol Simul. 2010;36:887–905.10.1080/08927022.2010.492834
   Web of Science ®Google Scholar
• Sahu NK, Shahi S, Sharma MC, et al. QSAR studies on imidazopyridazine derivatives as PfPK7 inhibitors. Mol Simul. 2011;37:752–765.10.1080/08927022.2010.547050
   Web of Science ®Google Scholar
• Xie A, Liao C, Li Z, et al. Quantitative structure-activity relationship study of histone deacetylase inhibitors. Curr Med Chem Anti-Cancer Agents. 2004;4:273–299.10.2174/1568011043352948
   PubMedGoogle Scholar
• Nair SB, Teli MK, Pradeep H, et al. Computational identification of novel histone deacetylase inhibitors by docking based QSAR. Comput Biol Med. 2012;42:697–705.10.1016/j.compbiomed.2012.04.001
   PubMed Web of Science ®Google Scholar
• Xiang YH, Zhang L, Zhang ZY. QSAR and docking studies on different series of histone deacetylase inhibitors (HDACIs). Lett Drug Des Discovery. 2012;9:367–378.
   Web of Science ®Google Scholar
• Jia Q, Cui X, Li L, et al. Quantitative structure–activity relationship for high affinity 5-HT 1A receptor ligands based on norm indexes. J Phys Chem B. 2015;119:15561–15567.10.1021/acs.jpcb.5b08980
   PubMed Web of Science ®Google Scholar
• Li L, Yan F, Xu X, et al. A QSAR model for predicting the anti HIV-1 activity of TIBO derivatives using the norm indexes. Bull Korean Chem Soc. 2016;37:923–930.10.1002/bkcs.2016.37.issue-6
   Web of Science ®Google Scholar
• Bozorgi AH, Bagheri M, Aslebagh R, et al. A structure–activity relationship survey of histone deacetylase (HDAC) inhibitors. Chemometr Intell Lab Syst. 2013;125:132–138.10.1016/j.chemolab.2013.04.001
   Web of Science ®Google Scholar
• Roy K, Kar S, Das RN. Chapter 7 - validation of QSAR models. In: Das KRKN, editor. Understanding the basics of QSAR for applications in pharmaceutical sciences and risk assessment. Boston (MA): Academic Press; 2015. p. 231–289.10.1016/B978-0-12-801505-6.00007-7
   Google Scholar
• Roy K, Das RN, Ambure P, et al. Be aware of error measures. Further studies on validation of predictive QSAR models. Chemometr Intell Lab Syst. 2016;152:18–33.10.1016/j.chemolab.2016.01.008
   Web of Science ®Google Scholar
• Xu X, Li L, Yan F, et al. Predicting solubility of fullerene C 60 in diverse organic solvents using norm indexes. J Mol Liq. 2016;223:603–610.10.1016/j.molliq.2016.08.085
   Web of Science ®Google Scholar
• Tropsha A. Best practices for QSAR model development, validation, and exploitation. Molecular Informatics. 2010;29:476–488.10.1002/minf.v29:6/7
   PubMed Web of Science ®Google Scholar
• Jaworska J, Nikolova-Jeliazkova N, Aldenberg T. QSAR applicabilty domain estimation by projection of the training set descriptor space: a review. Altern Lab Anim. 2005;33:445–459.
   PubMed Web of Science ®Google Scholar
• Tetko IV, Sushko I, Pandey AK, et al. Critical assessment of QSAR models of environmental toxicity against tetrahymena pyriformis: focusing on applicability domain and overfitting by variable selection. J Chem Inf Model. 2008;48:1733–1746.10.1021/ci800151 m
   PubMed Web of Science ®Google Scholar
• Gramatica P. Principles of QSAR models validation: internal and external. QSAR Comb Sci. 2007;26:694–701.10.1002/(ISSN)1611-0218
   Google Scholar
• Guo Y, Xiao J, Guo Z, et al. Exploration of a binding mode of indole amide analogues as potent histone deacetylase inhibitors and 3D-QSAR analyses. Bioorg Med Chem. 2005;13:5424–5434.10.1016/j.bmc.2005.05.016
   PubMed Web of Science ®Google Scholar